Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ban xia xie xin decoction + bismuth is a combination therapy that pairs a traditional Chinese medicine formula with bismuth-containing medication. The traditional Chinese medicine component (Ban xia xie xin decoction) consists of seven herbs: Zhi Ban Xia (Prepared Pinellia corm), Huang Qin (Scutellaria root), Huang Lian (Coptis rhizome), Gan Jiang (Dried Ginger root), Ren Shen (Asian Ginseng root), Zhi Gan Cao (Honey-baked Licorice root), and Da Zao (Chinese Date). The bismuth component typically includes bismuth pectin or bismuth potassium citrate along with antibiotics and a proton pump inhibitor. This combination therapy is primarily used for Helicobacter pylori eradication, particularly in cases with antibiotic resistance. The mechanism of action involves multiple pathways, including anti-inflammatory effects, inhibition of H. pylori urease activity, reduction of bacterial virulence factors, and enhancement of immune function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ban xia xie xin decoction + bismuth.